Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report)'s share price traded down 4.3% during mid-day trading on Monday after the company announced weaker than expected quarterly earnings. The stock traded as low as $23.13 and last traded at $23.24. 58,981 shares changed hands during trading, a decline of 78% from the average session volume of 269,650 shares. The stock had previously closed at $24.28.
The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same period in the prior year, the firm posted ($1.18) EPS.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on KMTS shares. Stifel Nicolaus started coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set a "buy" rating and a $28.00 price target on the stock. Wolfe Research started coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued an "outperform" rating and a $29.00 price target for the company. Piper Sandler began coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They set an "overweight" rating and a $27.00 price objective for the company. The Goldman Sachs Group decreased their target price on shares of Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating on the stock in a research note on Wednesday. Finally, Bank of America assumed coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They issued a "buy" rating and a $30.00 price target for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Kestra Medical Technologies currently has a consensus rating of "Moderate Buy" and a consensus target price of $27.50.
Check Out Our Latest Stock Report on Kestra Medical Technologies
Kestra Medical Technologies Trading Down 0.3 %
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Recommended Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
